| Date:                         | 5/16/2022  |
|-------------------------------|--|
| Your Name:                    | Emily Rogalski   |
| Manuscript Title:             | Alzheimer's Polygenic Hazard Score in SuperAgers: SuperGenes or SuperResilience? |
| Manuscript Number (if known): | TRCI-D-22-00050R1  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning of  | of the work   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None  Time frame: past 36 months   | Click the tab key to add additional rows.   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | Grant funding from NIA   |   |
| 3 | Royalties or<br>licenses  | None None  |   |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4  | Consulting fees   | None   |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events        | None None  |   |
| 6  | Payment for expert testimony  | None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | None   |   |
| 8  | Patents planned,<br>issued or<br>pending  | None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                       | None None  |   |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid | None None  |   |

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| 11  | Stock or stock<br>options   | [⊠] None   |   |
| 12  | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services | None   |   |
| 13  | Other financial or<br>non-financial<br>interests  | None   |   |
| Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form. |   |  |   |

| Date:                         | 5/16/2022  |
|-------------------------------|--|
| Your Name:                    | Sarah j Banks  |
| Manuscript Title:             | Alzheimer's Polygenic Hazard Score in SuperAgers: SuperGenes or SuperResilience? |
| Manuscript Number (if known): | TRCI-D-22-00050R1  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning   | of the work   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None  Time frame: past 36 month  | Click the tab key to add additional rows.   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | ☐ None  Grant funding from NIA, Alz Association and CDPH                                     |   |
| 3 | Royalties or<br>licenses  | None None  |   |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4  | Consulting fees   | □ None  I consult for a study run by Boston University, on chronic traumatic encephelopathy  |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events        | None   |   |
| 6  | Payment for expert testimony  | None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | None   |   |
| 8  | Patents planned,<br>issued or<br>pending  | None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                       | I am on a DSMB for Barrow Health, Dr. Marwan Sabbagh   |   |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid | None   |   |

|      |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|--|---|
| 11   | Stock or stock<br>options   | None   |   |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services  | None   |   |
| 13   | Other financial or<br>non-financial<br>interests  | None   |   |
| Plea | Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |

| Date:  | 5/19/2022  |  |
|--|--|--|
| Your Name:   | Changiz Geula  |  |
| Manuscript Title:  | Alzheimer's Polygenic Hazard Score in SuperAgers: SuperGenes or SuperResilience? |  |
| Manuscript Number (if known):  | anuscript Number (if known): TRCI-D-22-00050R1                                   |  |
| In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. |  |  |
| The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.   |  |  |

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)    | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
|   |   | Time frame: Since the initial planning  | of the work   |
|   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | NIA Grant: R01AG067781 NIA Grant: U19AG073153 NIA Grant: P30AG072977  Time frame: past 36 month | Institution Institution Institution   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None  NINDS Grant: R01NS085770  NINDS Grant: R24NS104160  | Institution Institution   |
| 3 | Royalties or licenses   | None None   |   |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4  | Consulting fees   | None None  |   |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None   |   |
| 6  | Payment for expert testimony  | ⊠ None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | None   |   |
| 8  | Patents planned,<br>issued or<br>pending  | None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                       | None   |   |

|          |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----------|---|--|---|
| 11       | Stock or stock<br>options   | None   |   |
| 12       | Receipt of equipment, materials, drugs, medical writing, gifts or other services  | None   |   |
| 13       | Other financial or<br>non-financial<br>interests  | ⊠  None  |   |
| Plea [⊠] | Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |

| Date:                         | 5/23/2022  |
|-------------------------------|--|
| Your Name:                    | Beth Makowski-Woidan   |
| Manuscript Title:             | Alzheimer's Polygenic Hazard Score in SuperAgers: SuperGenes or SuperResilience? |
| Manuscript Number (if known): | Click or tap here to enter text.   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   |        | e all entities with whom you have this onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |  |
|---|---|--------|---|---|--|
|   |   | relati |   |   |  |
|   |   |        | Time frame: Since the initial planning  | of the work   |  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. |        | None  | Click the tab key to add additional rows.   |  |
|   |   |        | Time frame: past 36 month   | s   |  |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  |        | None  |   |  |
| 3 | Royalties or<br>licenses  |        | None  |   |  |

| ľ  |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4  | Consulting fees   | None   |   |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None   |   |
| 6  | Payment for expert testimony  | None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | None   |   |
| 8  | Patents planned,<br>issued or<br>pending  | None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                       | [⊠] None   |   |

|          |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----------|---|--|---|
| 11       | Stock or stock<br>options   | None   |   |
| 12       | Receipt of equipment, materials, drugs, medical writing, gifts or other services  | None   |   |
| 13       | Other financial or<br>non-financial<br>interests  | None   |   |
| Plea [🖂] | Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |

| Date:                         | 8/26/2021  |
|-------------------------------|--|
| Your Name:                    | Barbara Spencer  |
| Manuscript Title:             | Alzheimer's Polygenic Hazard Score in SuperAgers: SuperGenes or SuperResilience? |
| Manuscript Number (if known): | TRCI-D-22-00050R1  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   |     | l entities with whom you have this<br>ship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|-----|--|---|
|   |   |     | Time frame: Since the initial planning   | of the work   |
|   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. |     | one  | Click the tab key to add additional rows.   |
|   |   | f 1 | Time frame: past 36 month  | S   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | No  | one  |   |
| 3 | Royalties or<br>licenses  | No. | one  |   |

|    |  |   | comments (e.g., if payments were to your institution) |
|----|--|---|---|
| 4  | Consulting fees  | None None   |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None None   |   |
| 6  | Payment for expert testimony   | None  |   |
| 7  | Support for attending meetings and/or travel   | ⊠  None   |   |
| 8  | Patents planned,<br>issued or<br>pending   | Image: square of the square o |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | ⊠ None  |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | None None   |   |

|          |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----------|---|--|---|
| 11       | Stock or stock<br>options   | None   |   |
| 12       | Receipt of equipment, materials, drugs, medical writing, gifts or other services  | None   |   |
| 13       | Other financial or<br>non-financial<br>interests  | None   |   |
| Plea [🖂] | Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |

| Date:                         | 5/26/2022  |
|-------------------------------|--|
| Your Name:                    | James Brewer, M.D., Ph.D.  |
| Manuscript Title:             | Alzheimer's Polygenic Hazard Score in SuperAgers: SuperGenes or SuperResilience? |
| Manuscript Number (if known): | TRCI-D-22-00050R1  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning o   | of the work   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None   | Click the tab key to add additional rows.   |
|   |   | Time frame: past 36 months   | S   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | NIH P30AG062429  |   |
| 3 | Royalties or<br>licenses  | None None  |   |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4  | Consulting fees   | □ None   |   |
|    |   | Human Longevity, Inc.  | paid to me  |
|    |   |  |   |
| 5  | Payment or<br>honoraria for<br>lectures,                      | ⊠ None   |   |
|    | presentations,<br>speakers                                    |  |   |
|    | bureaus,<br>manuscript<br>writing or<br>educational<br>events |  |   |
| 6  | Payment for expert testimony                                  | ⊠ None   |   |
|    |   |  |   |
|    |   |  |   |
| 7  | Support for attending   | [⊠] None   |   |
|    | meetings and/or<br>travel                                     |  |   |
|    |   |  |   |
| 8  | Patents planned,<br>issued or                                 | [⊠] None   |   |
|    | pending   |  |   |
|    |   |  |   |
| 9  | Participation on<br>a Data Safety                             | □ None   |   |
|    | Monitoring<br>Board or  | CorTechs.ai Human Longevity, Inc.  | advisory board advisory board   |
|    | Advisory Board  |  | ·   |
| 10 | Leadership or fiduciary role in                               | None   |   |
|    | other board,<br>society,                                      |  |   |
|    | committee or advocacy group,                                  |  |   |
|    | paid or unpaid  |  |   |

|      |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|--|---|
| 11   | Stock or stock options  | Human Longevity, Inc CorTechs.ai   | made to me<br>made to me  |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services  | None   |   |
| 13   | Other financial or<br>non-financial<br>interests  | None   |   |
| Plea | Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |

| Date:                         | 5/26/2022  |
|-------------------------------|--|
| Your Name:                    | Marsel Mesulam   |
| Manuscript Title:             | Alzheimer's Polygenic Hazard Score in SuperAgers: SuperGenes or SuperResilience? |
| Manuscript Number (if known): | TRCI-D-22-00050R1  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|     |   |             | Il entities with whom you have this ship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----|---|-------------|--|---|
| Tim | e frame: Since the ir   | nitial plan | nning of the work  |   |
| 1   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | ⊠ N         | lone   | Click the tab key to add additional rows.   |
| Tim | e frame: past 36 mo   | nths        |  |   |
| 2   | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | [⊠] N       | lone   |   |
| 3   | Royalties or licenses   | × N         | lone   |   |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|---|
| 4  | Consulting fees   | None paid to me   |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None None   |
| 6  | Payment for expert testimony  | None  |
| 7  | Support for attending meetings and/or travel  | None  |
| 8  | Patents planned,<br>issued or<br>pending  | None  |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | None  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                       | None None   |

|      |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|--|---|
| 11   | Stock or stock options  | None   |   |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services  | None   |   |
| 13   | Other financial or non-financial interests  | None   |   |
| Plea | Please place an "X" next to the following statement to indicate your agreement:  I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |

21 12/13/2021 ICMJE Disclosure Form

| Date:                         | 5/31/2022  |
|-------------------------------|--|
| Your Name:                    | Sandra Weintraub   |
| Manuscript Title:             | Alzheimer's Polygenic Hazard Score in SuperAgers: SuperGenes or SuperResilience? |
| Manuscript Number (if known): | TRCI-D-22-00050R1  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   |  |      | ies with whom you have this<br>rindicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|------|--|---|
|   |  |      | Time frame: Since the initial planning                             | of the work   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | Time frame: past 36 month  | Click the tab key to add additional rows.   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).   | None | Time traine, past 30 mon.  |   |
| 3 | Royalties or<br>licenses   | None |  |   |

12/13/2021 ICMJE Disclosure Form

22 12/13/2021

1

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 4  | Consulting fees  | None   |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None   |   |
| 6  | Payment for expert testimony   | None   |   |
| 7  | Support for attending meetings and/or travel   | None   |   |
| 8  | Patents planned,<br>issued or<br>pending   | None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | None   |   |

2 12/13/2021 ICMJE Disclosure Form

|      |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)                 | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|--|---|
| 11   | Stock or stock options  | None   |   |
| 12   | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services | None   |   |
| 13   | Other financial or<br>non-financial<br>interests  | None   |   |
| Plea | •   | t to the following statement to indicate your agreeme<br>answered every question and have not altered the wo |   |

06/01/22

12/13/2021

ICMJE Disclosure Form

24

| Date:                         | 6/1/2022   |
|-------------------------------|--|
| Your Name:                    | Anders M. Dale, PhD  |
| Manuscript Title:             | Alzheimer's Polygenic Hazard Score in SuperAgers: SuperGenes or SuperResilience? |
| Manuscript Number (if known): | TRCI-D-22-00050R1  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|     |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----|---|---|---|
| Tim | e frame: Since the in   | nitial planning of the work   |   |
| 1   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None  | Click the tab key to add additional rows.   |
| Tim | e frame: past 36 mo   | nths  |   |
| 2   | Grants or contracts from any entity (if not indicated in item #1 above).  | Dr. Dale reports that he was a Founder of and holds equity in CorTechs Labs, Inc., and serves on its Scientific Advisory Board. He is a member of the Scientific Advisory Boards of Human Longevity, Inc., and the Mohn Medical Imaging and Visualization Centre. He receives funding through research grants from GE Healthcare to UCSD.  The terms of these arrangements have been reviewed by and approved by UCSD in accordance with its conflict of interest policies. |   |

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 3  | Royalties or<br>licenses   | None None  |   |
| 4  | Consulting fees  | None None  |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None None  |   |
| 6  | Payment for expert testimony   | None None  |   |
| 7  | Support for attending meetings and/or travel   | None   |   |
| 8  | Patents planned,<br>issued or<br>pending   | None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | None   |   |
| 10 | Leadership or fiduciary role in other board,   | None   |   |

|             |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-------------|--|--|---|
|             | society,<br>committee or<br>advocacy group,<br>paid or unpaid  |  |   |
| 11          | Stock or stock options   | None   |   |
| 12          | Receipt of equipment, materials, drugs, medical writing, gifts or other services                                     | None   |   |
| 13          | Other financial or non-financial interests   | None   |   |
| r 1         | Please place an "X" next to the following statement to indicate your agreement:                                      |  |   |
| $\boxtimes$ | I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |